Skip to main navigation

Main navigation

  • About
    • Who We Are
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Technology
  • Therapeutic Areas
    • Acne Vulgaris
    • Subtype II Papulopustular Rosacea
    • Palmoplantar Keratoderma
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Analyst Coverage
    • Financial Information
    • Stock Information
    • Shareholder Services
  • Media
  • Contact

Press Releases

Date Title  
Jan 27, 2023
Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
 
Jan 27, 2023
Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
 
Nov 10, 2022
Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
 
Oct 03, 2022
Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
 
Aug 04, 2022
Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
 
Jun 02, 2022
Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
 
Jun 01, 2022
Summary ToggleSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
 
May 17, 2022
Summary ToggleSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
 
May 13, 2022
Summary ToggleSol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
 
Apr 25, 2022
Summary ToggleSol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
 

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 93 results

Investor Relations

  • Investor Overview
  • Press Releases
  • Events & Presentations
    • Events
  • Corporate Governance
    • Documents and Charters
    • Committee Composition
  • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Proxy Statement
  • Stock Information
    • Stock Quote & Chart
  • Shareholder Services
    • FAQs
    • Contact
    • Email Alerts

Shareholder Tools

Print
Print
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds

Who We Are

We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

What We Do

Footer What We Do

  • About
  • Technology
  • Pipeline

Get In Touch

Footer Get In Touch

  • Contact Us
  • Partnering

Subscribe!

Subscribe to receive updates
Sign-up

© 2023 Sol-Gel Technologies Ltd. All Rights Reserved